0000950170-24-050844.txt : 20240430 0000950170-24-050844.hdr.sgml : 20240430 20240430210210 ACCESSION NUMBER: 0000950170-24-050844 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240429 FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fenton Mary Kay CENTRAL INDEX KEY: 0001378589 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 24899618 MAIL ADDRESS: STREET 1: ACHILLION PHARMACEUTICALS STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Therapeutics, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, Inc. DATE OF NAME CHANGE: 20210225 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4 1 ownership.xml 4 X0508 4 2024-04-29 0001789972 Cullinan Therapeutics, Inc. CGEM 0001378589 Fenton Mary Kay C/O CULLINAN THERAPEUTICS, INC. ONE MAIN STREET, SUITE 1350 CAMBRIDGE MA 02142 false true false false Chief Financial Officer false Stock Option (Right to Buy) 27.12 2024-04-29 4 A false 200000 0.00 A 2034-04-29 Common Stock 200000 200000 D The option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, 25% of which will become vested and exercisable on April 29, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. /s/ Jacquelyn Sumer, Attorney-in-Fact 2024-04-30